Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. is informing holders that on February 18, 2026 the majority stockholder approved an amendment authorizing the Board to effect, at its discretion, a reverse stock split of up to 1-for-10. The Board may set any whole-number ratio up to 1-for-10 or abandon the action prior to filing.
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of February 18, 2026, there were 4,905,945 shares outstanding; a 1-for-10 split would reduce outstanding shares to 490,595, subject to rounding.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.
Amendment No. 1 to a Schedule 13G/A reports that three related Altium entities jointly filed a disclosure concerning Sunshine Biopharma, Inc. The filing names the fund, its investment adviser and the fund's general partner and explains their potential relationships to any securities of the issuer.
The filing explicitly reports 0 shares (0%) beneficially owned by each reporting person and states that the securities were not acquired for the purpose of changing or influencing control of the issuer. The document clarifies parties who could be deemed to have a relationship to beneficial ownership while also affirming that no holdings are reported in this statement.
Sunshine Biopharma Inc. reported six-month revenue of $18,311,571, up 8.7% year-over-year, with gross profit of $6,153,292 as cost of goods sold fell to 66.4% of sales from 72.0% a year earlier, reflecting improved procurement and pricing.
The company recorded a net loss of $2,950,605 for the six months, driven in part by a $1,061,809 impairment of certain intangible product licenses and higher consulting and salary costs. Operating cash use was $2,987,267 in the period, while cash and equivalents stood at $10,305,320. Financing activities provided $3,948,372 (including registered direct offering net proceeds of $1,828,596 and warrant exercises), and management states existing cash and expected sales are sufficient to fund operations for the next 24 months. The company disclosed a demand letter from its former Nora Pharma president seeking CAD 7,307,025 (~$5.3M), with no accrual recorded. Outstanding potential dilution includes 15,577,965 Series B warrants (as adjusted) and 4,555,945 common shares issued and outstanding.